US FDA Nominee Makes A Good First Impression, But This Is Still An Odd Transition
Executive Summary
Stephen Hahn mostly coasted through a confirmation hearing to be the next FDA commissioner – but he still didn’t really give any indication of why he wants the job.
You may also be interested in...
Playing It Safe? Hahn's Biosimilar View
US FDA Commissioner nominee gave a general, scripted answer to a question about biologic patents, but did Stephen Hahn inadvertently go against the agency's stance on the issue?
Hahn Confirmation Hearing: Solid Performance Light On Substance
US FDA commissioner nominee Stephen Hahn does not offer much detail on his policy positions; Senate confirmation could be completed by the end of the year.
The Absurd Innovation Debate: Dueling Views Of HR 3 Miss The Point
White House Council of Economic Advisors says US House drug price “negotiation” bill will reduce the number of innovative medicines by 100 over a decade; the Congressional Budget Office says more like 8-15. Both analyses miss the point – but also show that industry is losing a crucial piece of political ground.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: